Novel S-Layer Intranasal and Oral COVID-19 Vaccine Could Decrease Severity of SARS-CoV-2 Infection

Scientists are developing a novel S-layer SARS-CoV-2 vaccine that can be administered by an intranasal or oral route and would induce a sufficient immune response to prevent a severe form of COVID-19, which causes morbidity and often mortality.

Avalon GloboCare Corp. (Freehold, NJ, USA), a clinical-stage global developer of cell-based technologies and therapeutics, is developing the S-layer vaccine in partnership with the University of Natural Resources and Life Sciences (BOKU Vienna, Austria). BOKU’s Professor Uwe B. Sleytr, an eminent member of the Austrian Academy of Sciences, is a pioneer of applied surface layer (S-layer) nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells. The research is part of an ongoing and broader collaboration between Avalon and BOKU that will utilize S-layer technology to accelerate additional vaccine programs for other respiratory infections including different strains of the flu (influenza A/B), respiratory syncytial virus (RSV), and other viruses. As part of the partnership, Avalon is also actively exploring other practical uses of S-layer technology including targeted drug delivery, diagnostic devices, and therapeutic applications.


The COVID-19 vaccine candidate is derived from a fusion of an S-layer viral particle mimic with the SARS-CoV-2 spike protein and could be delivered non-invasively via the nasal or oral passageways, rather than a needle-based injection into the muscle or under the skin. The S-layer protein-based vaccine is expected to both decrease the severity of a SARS-CoV-2 infection, preventing the more severe respiratory inflammation and organ damage seen in many COVID-19 patients, and build immunity against the virus. The investigators have already made substantial progress by developing the proprietary techniques necessary to synthesize conjugate vaccines consisting of an S-layer artificial viral envelope linked to a viral antigen. As a proof of concept, they have also shown that these types of protein conjugate vaccine candidates are able to elicit immune-protective antibody responses.

“We are encouraged by the progress we have made so far to develop a novel COVID-19 vaccine during this unprecedented world-wide health crisis,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We are working swiftly and diligently with BOKU to complete the laboratory testing and characterization of the S-layer fusion protein SARS-CoV-2 vaccine candidate. We believe that our novel vaccine approach has the potential to be effective. Importantly, this vaccine candidate could be manufactured and delivered more rapidly compared to traditional vaccines, providing access and immunization to a larger population of people around the globe to help combat the COVID-19 pandemic.”

Related Links:
Avalon GloboCare Corp.
University of Natural Resources and Life Sciences